Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel®, Testosterone 1% gel therapy, in hypogonadal men

References

• Mulligan T, Frick M F, Zuraw Q C, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762–769
   PubMed Web of Science ®Google Scholar
• Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hichgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med 2007; 4: 1056–1069
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Oh J Y, Barrett-Connor E, Wedick N M, Wingard D L. Endogenous sex hormones and development of Type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 2002; 25: 55–60
   PubMed Web of Science ®Google Scholar
• Kupelian V, Page S T, Araujo A B, Travison T G, Bremner W J, McKinlay J B. J. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. Clin Endocrinol Metab 2006; 91: 843–850
   Google Scholar
• Eckel R H, Grundy S M, Zimmet P Z. The metabolic syndrome. Lancet 2005; 365: 1415–1428
   PubMed Web of Science ®Google Scholar
• Lakka H M, Laaksonen D E, Lakka T A, Niskanen L K, Kumpusalo E, Tuomilehto J, Salonen J T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M-R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56–58
   PubMedGoogle Scholar
• Lunenfeld B, Saad F, Hoesl C E. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: Scientific background and rationale. Aging Male 2005; 8: 59–74
   PubMedGoogle Scholar
• The Endocrine Society. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010
   PubMed Web of Science ®Google Scholar
• Swerdloff R S, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A M, Snyder P J, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 4500–4510
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff R S, Iranmanesh A, Dobs A, Snyder P J, Cunningham G, Matsumoto A M, Weber T, Berman N, Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839–2853
   PubMed Web of Science ®Google Scholar
• Heinemann L A, Saad F, Heinemann K, Thai D M. Can results of the Aging Males' Symptoms (AMS) scale predict those of screening scales for androgen deficiency?. Aging Male 2004; 7: 211–218
   PubMedGoogle Scholar
• Beutel M E, Wiltink J, Hauck E W, Auch D, Behre H M, Brähler E, Weidner W, the Hypogonadism Investigator Group. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 2005; 47: 749–755
   PubMed Web of Science ®Google Scholar
• Heinemann L A. Aging Male's Symptoms scale: A standardized instrument for the practice. J Endocrinol Invest 2005; 28(Suppl 11)34–38
   PubMedGoogle Scholar
• Daig I, Heinemann L A, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai D M. The Aging Males' Symptoms (AMS) scale: Review of its methodological characteristics. Health Qual Life Outcomes 2003; 1: 77
   PubMedGoogle Scholar
• Heinemann L A, Moore C, Dinger J C, Stoehr D. Sensitivity as outcome measure of androgen replacement: The AMS scale. Health Qual Life Outcomes 2006; 4: 23
   PubMed Web of Science ®Google Scholar
• Heinemann L A, Saad F, Zimmermann T, Novak A, Myon E, Badia X, Potthoff P, T'Sjoen G, Pöllänen P, Goncharow N P, Kim S, Giroudet C. The Aging Males' Symptoms (AMS) scale: Update and compilation of international versions. Health Qual Life Outcomes 2003; 1: 15
   PubMedGoogle Scholar
• Moore C, Huebler D, Zimmermann T, Heinemann L A, Saad F, Thai D M. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80–87
   PubMed Web of Science ®Google Scholar
• Rosen R C, Riley A, Wagner G, Osterloh I H, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830
   PubMed Web of Science ®Google Scholar
• Rosen R C, Cappelleri J C, Gendrano N. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002; 14: 226–244
   PubMed Web of Science ®Google Scholar
• Chiang H S, Hwang T I, Hsui Y S, Lin Y C, Chen H E, Chen G C, Liao C H. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function. Int J Impot Res 2007; 19: 411–417
   PubMed Web of Science ®Google Scholar
• Yassin A A, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007; 4: 497–501
   PubMed Web of Science ®Google Scholar
• Smets E M, Garssen B, Bonke B, De Haes J C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychsom Res 1995; 39: 315–325
   PubMed Web of Science ®Google Scholar
• Grundy S M, Cleeman J I, Daniels S R, Donato K A, Eckel R H, Franklin B A, Gordon D J, Krauss R M, Savage P J, Smith S C, Spertus J A, Costa F, American Heart Association National Heart Lung and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005; 112: 2735–2752
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher A D, Chiarini V, Forti G, Maggi M. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007; 4: 789–796
   PubMed Web of Science ®Google Scholar
• Moore C, Huebler D, Zimmermann T, Heinemann L A, Saad F, Thai D M. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80–87
   PubMed Web of Science ®Google Scholar